Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

APSTZD 3

Phase 2Small molecule

AApsen Farmaceutica S.A.

APSTZD 3 is one of 42 small molecule programs targeting Insomnia. It is currently in Phase 2.

1

Indications

1

Total Trials

1

Active Trials

41

Competitors

Pipeline

Status by Indication[3][1]

Indication

InsomniaRecruiting

InsomniaPhase 2

Recruiting

Competition

Competitive Landscape

50 competitors in Insomnia

#DrugCompanyPhaseTrials

Rozerem

Dayvigo

Ambien

PPurdue Pharma LP

Lunesta

Akero Therapeutics

Lexapro

Belsomra

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Raldesy

Quviviq

Idorsia Pharmaceuticals Ltd.

Seroquel

EEngelhard Arzneimittel GmbH & Co.KG

Bayer Aspirin

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

Insomnia

NCT07420816

Clinical

Trials by Indication[1]

Insomnia1 trial

Phase II Randomized, Multicenter, Double-blind, Doubledummy, Parallel Clinical Trial to Evaluate the Efficacy and Safety of APSTZD in the Treatment of Insomnia Disorder

Recruiting·AApsen Farmaceutica S.A.·Phase 2·NCT07420816·222 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for APSTZD 3. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — APSTZD 3 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for APSTZD 3. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Apsen Farmaceutica S.A. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AApsen Farmaceutica S.A.

Related News